Browse EX-10 agreements

SEPARATION AGREEMENT

May 22, 2026

This Separation Agreement (this “Agreement”) is made on the date first written above by and between Tempest Therapeutics, Inc., a Delaware corporation (the “Company”), and Christine Pellizzari (the “Director”).

In consideration of the mutual covenants set forth herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

1.

Separation Date. The Director hereby resigns from the Company’s Board of Directors and all committees thereof effective as of May 22, 2026 (the “Separation Date”).

2.

Director Compensation. The Director hereby waives all rights to any accrued and unpaid director compensation. Nothing in this Agreement shall affect the Director’s rights under the Director’s outstanding stock option awards or the Director’s ownership of shares of capital stock of the Company, subject to the terms of the applicable award agreement between the Director and the Company and the terms of the Company’s Amended and Restated 2019 Equity Incentive Plan.

3.

…

SEPARATION AGREEMENT

May 22, 2026

This Separation Agreement (this “Agreement”) is made on the date first written above by and between Tempest Therapeutics, Inc., a Delaware corporation (the “Company”), and Stephen Brady (the “Director”).

In consideration of the mutual covenants set forth herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

1.

Separation Date. The Director hereby resigns from the Company’s Board of Directors and all committees thereof effective as of May 22, 2026 (the “Separation Date”).

2.

Director Compensation. The Director hereby waives all rights to any accrued and unpaid director compensation. Nothing in this Agreement shall affect the Director’s rights under the Director’s outstanding stock option awards or the Director’s ownership of shares of capital stock of the Company, subject to the terms of the applicable award agreement between the Director and the Company and the terms of the Company’s Amended and Restated 2019 Equity Incentive Plan.

3.

…

SECURITIES PURCHASE AGREEMENT

THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and made effective as of August 12, 2026, between Professional Diversity Network, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act (as defined below), the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:

ARTICLE I.
DEFINITIONS

1.1 Definitions. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings set forth in this Section 1.1:

“Acquiring Person” shall have the meaning ascribed to such term in Section 4.5.

“Action” shall have the meaning ascribed to such term in Section 3.1(j).

…

PLACEMENT AGENCY AGREEMENT

August 12, 2026

Roth Capital Partners, LLC

888 San Clemente Drive, Suite 400

Newport Beach, CA 92660

Ladies and Gentlemen:

Introduction. Subject to the terms and conditions herein (this “Agreement”), between Roth Capital Partners, LLC (the “Placement Agent”) as placement agent and Aptevo Therapeutics Inc. a Delaware corporation (the “Company”), the Placement Agent shall act as lead placement agent in connection with (i) the inducement of the exercise of warrants (the “Inducement Warrant Shares”) from the holders of June 2025 Common Warrants, April 2025 Common Warrants and December 2024 Common Warrants (together the “Existing Warrants”) of the Company (the “Holders”) and issuance of new warrants (the “Inducement Warrants”, collectively with the Inducement Warrant Shares, the “Inducement Securities”) (the “Inducement”) and (ii) the sale of up to an aggregate of $3,472,683.24 of unregistered securities (the “ PIPE Securities”) of the Company, including, but not limited to, 0 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), pre-funded common stock purchase warrants to purchase up to an aggregate of 254,922 shares of Common Stock (the “Pre-Funded Warrants”), and common stock purchase warrants to purchase up to an aggregate of 1,274,610 shares of Common Stock (the “Common Warrants” and, collectively with the Pre-Funded Warrants, the “PIPE Warrants”, and together with the Inducement Warrants the “Warrants”) collectively with Shares and the shares of common stock issuable upon exercise of the

…

REGISTRATION RIGHTS AGREEMENT

This Registration Rights Agreement (this “Agreement”) is made and entered into as of August 12, 2026, between Aptevo Therapeutics Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).

This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and each Purchaser (the “Purchase Agreement”) and the Warrant Inducement Agreement, dated as of the date hereof, between the Company and the Purchaser (the “Inducement Letter”).

The Company and each Purchaser hereby agrees as follows:

1. Definitions.

Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the Purchase Agreement.As used in this Agreement, the following terms shall have the following meanings:

“Advice” shall have the meaning set forth in Section 6(c).

…

SECURITIES PURCHASE AGREEMENT

This Securities Purchase Agreement (this “Agreement”) is dated as of August 12, 2026, between Aptevo Therapeutics Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).

WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act (as defined below), and Rule 506 promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:

ARTICLE I.

DEFINITIONS

1.1

Definitions. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings set forth in this Section 1.1:

“Acquiring Person” shall have the meaning ascribed to such term in Section 4.5.

“Action” shall have the meaning ascribed to such term in Section 3.1(j).

…

Aptevo Therapeutics inc.

August 12, 2026

Holder of the June 2025 Common Stock Purchase Warrants, April 2025 Common Stock Purchase Warrants and December 2024 Common Stock Purchase Warrants

Re:	Inducement Offer to Exercise Common Stock Purchase Warrants

Dear Holder:

Aptevo Therapeutics Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) (i) the opportunity to receive new warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) and (ii) a reduction in the Exercise Price (as defined in the respective Existing Warrants) in consideration for exercising by you for cash at a Reduced Exercise Price (as defined below), as set forth on the signature page hereto, the June 2025 Common Stock Purchase Warrants (the “June 2025 Warrants”) currently held by you and issued on June 20, 2025 attached hereto as Exhibit A-1, the April 2025 Common Stock Purchase Warrants (the “April 2025 Warrants”) currently held by you and issued on April 3, 2025 attached hereto as Exhibit A-2,and the December 2024 Common Stock Purchase Warrants (the “December 2024 Warrants”) currently held by you and issued on December 12, 2024 attached hereto as Exhibit A-3. The December 2024 Warrants, together with the June 2025 Warrants and April 2025 Warrants the “Existing Warrants”.

…

EXECUTION COPY

TENTH OMNIBUS AMENDMENT

This TENTH OMNIBUS AMENDMENT, dated as of August 12, 2026 (this “Amendment”), is entered into by and among ALLIANCE LAUNDRY SYSTEMS LLC, a Delaware limited liability company (“ALS”), ALLIANCE LAUNDRY EQUIPMENT RECEIVABLES 2015 LLC, a Delaware limited liability company (“ALER”), ALLIANCE LAUNDRY EQUIPMENT RECEIVABLES TRUST 2015-A, a Delaware statutory trust (the “Issuer”), THE BANK OF NEW YORK MELLON, a New York banking corporation, as trustee under the Indenture (the “Indenture Trustee”), each of the NOTE PURCHASERS listed on the signature pages hereto (collectively, the “Note Purchasers”), each of the FUNDING AGENTS for the Purchaser Groups listed on the signature pages hereto (collectively, the “Funding Agents”) and PNC BANK, NATIONAL ASSOCIATION, as administrative agent for the Note Purchasers (the “Administrative Agent”).

BACKGROUND:

1.ALS, ALER and the Issuer are parties to that certain Amended and Restated Pooling and Servicing Agreement, dated as of June 8, 2018 (as amended, restated, supplemented or otherwise modified through the date hereof, together with all exhibits and schedules thereto, the “Pooling and Servicing Agreement”);

…

AMENDMENT NO. 14 TO CREDIT AGREEMENT

AMENDMENT NO. 14, dated as of May 27, 2026 (this “Amendment”) to the Credit Agreement, dated as of December 16, 2020, among Legence Holdings LLC (f/k/a Refficiency Holdings LLC), a Delaware limited liability company (the “Borrower”), the other Guarantors party thereto, the lenders party thereto and Jefferies Finance LLC, as Administrative Agent (in such capacity, the “Administrative Agent”), Collateral Agent, Swing Line Lender and an L/C Issuer (as amended, restated, amended and restated, modified and supplemented from time to time prior to the date hereof, the “Credit Agreement” and as further amended by this Amendment, the “Amended Credit Agreement”); capitalized terms used and not otherwise defined herein shall have the meanings assigned to such terms in the Credit Agreement.

WHEREAS, the Borrower has requested that certain amendments and modifications to the Credit Agreement be effected pursuant to Section 2.15 of the Credit Agreement, which permits the Borrower to obtain Refinancing Term Loans (or Commitments in respect of Refinancing Term Loans) from Additional Amendment No. 14 Refinancing Lenders (as defined below) in respect of all or a portion of any existing Refinancing Term Loans;

…

​

Exhibit 10.1

SEVERANCE AGREEMENT

THIS SEVERANCE AGREEMENT (“Agreement”) is made as of August 11, 2026 (the “Effective Date”), by and between MaxCyte, Inc., a Delaware corporation (the “Company”), and Parmeet Ahuja (the “Executive”).

WHEREAS, the Company considers it essential to its best interests and to the best interests of its shareholders and customers to foster the continuous employment of its key management personnel; and

WHEREAS, the Company desires to provide the Executive with certain severance benefits in the event the employment of the Executive is terminated after the Effective Date under certain circumstances.

NOW, THEREFORE, in consideration of the premises and the mutual covenants herein contained, the Company and the Executive hereby agree as follows:

1.Defined Terms. Definitions of certain capitalized terms used in this Agreement are provided in Section 8 and elsewhere in this Agreement.

2.Term of Agreement. This Agreement shall become effective on the Effective Date and shall remain in effect indefinitely thereafter. Notwithstanding the foregoing, this Agreement shall terminate upon the earlier of (i) the Date of Termination, in the event the Executive’s employment is terminated by the Company for Cause, or (ii) the expiration of the applicable Severance Period.

…

CIBUS US LLC EMPLOYEE PROPRIETARY INFORMATION, INVENTIONS, NON-COMPETE AND NON-SOLICIT AGREEMENT 1 Statement Regarding Employee Proprietary Information, Inventions, Non-Compete and Non-Solicit Agreement Attached to this statement is your Employee Proprietary Information, Inventions, Non-Compete and Non-Solicit Agreement (the “Agreement”) with Cibus US LLC, a company organized under the laws of Delaware (the “Company”). Please take the time to review the Agreement carefully. It contains material restrictions on your right to disclose or use, during or after your employment, certain information and technology learned or developed by you (either alone or jointly with others) during your employment, as well as other important restrictions. The Company considers this Agreement to be very important to the protection of its business. If you have any questions concerning the Agreement, you may wish to consult an attorney. Managers, legal counsel, and others in the Company are not authorized to give you legal advice concerning the Agreement. If you have read and understand the Agreement, and if you agree to its terms and conditions, please return a fully executed copy of it to the Company, retaining one copy for yourself. REVIEWED AND UNDERSTOOD: Signature: Name: Date:

---

…

Page 1 of 8 EMPLOYEE PROPRIETARY INFORMATION, NONDISCLOSURE AND INNOVATION ASSIGNMENT AGREEMENT In consideration for my new or continued employment, the wages and benefits paid to me, and the access I will be provided to my employer’s confidential and proprietary information, I agree to the following with my employer, Cibus US LLC (“Company”): 1. “Proprietary Information” Defined. “Proprietary Information” means information that was developed, created, derived, or discovered by Company, which was generated by me for the Company in the course of my employment, or which became known by, or was conveyed to Company, which has commercial value in Company’s business. Proprietary Information includes, but is not limited to, information related to Innovations (as defined in Section 2 below); contracts; sales and marketing materials or strategies; Company’s client lists and prospective client lists (including the names, addresses, telephone numbers and account numbers of Company’s clients, Company’s trade history with each client, pricing models, and all other information on Company’s client and prospective client lists); Company’s employee lists (including the names, addresses, and telephone numbers of Company’s employees); vendor and subcontractor lists and all other information regarding Company’s vendors or subcontractors; training materials, policies and procedures; methods, techniques, and expertise, including proprietary installation procedures; software programs; Company’s financial information; and all concepts, plans, proposals or information about Company’s current,

…